Stock 300298 SINOCARE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sinocare Inc.

Equities

300298

CNE100001CJ0

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-19 pm EDT 		5-day change 1st Jan Change
24.54 CNY +4.43% Intraday chart for Sinocare Inc. +4.60% -19.28%
Apr. 26 Sinocare Inc. Proposes Final Dividend for 2023 CI
Apr. 25 Sinocare Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 46% by 2026.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SINOCARE INC. Stock Sinocare Inc.
-19.28% 1.8B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.94% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
+2.97% 114B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.02% 68.29B
A
DEXCOM, INC. Stock DexCom, Inc.
+5.58% 52.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+7.44% 44.3B
B-
HOYA CORPORATION Stock Hoya Corporation
+6.67% 42.73B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+25.47% 32.52B
B
TERUMO CORPORATION Stock Terumo Corporation
+20.03% 26.02B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-2.16% 25.91B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300298 Stock
  4. Ratings Sinocare Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW